Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia

Kristin Martin-Cook, Linda S. Hynan, Kathleen Rice-Koch, Doris A. Svetlik, Myron F. Weiner

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Background: We report on the responsiveness of a previously validated quality-of-life scale, the Quality of Life in Late-Stage Dementia scale (QUALID), as an outcome measure in a clinical trial of two psychotropic medications. Methods: Secondary analyses were conducted comparing outcome measures used in a randomized double-blind trial of two antipsychotics (olanzapine and risperidone) for the treatment of dementia-related behavioral symptoms. The QUALID was completed for 31 of the patients in addition to several measures of behavior-related dementia symptoms including the Neuropsychiatric Inventory, the Withdrawn Behavior subscale of the Multidimensional Observation Scale for Elderly Subjects, the Mini-Mental State Examination, and the Clinical Global Impression. Measures of safety and adverse effects included the Simpson-Angus Scale and records of specific adverse events. Results: A significant positive relationship was found between QUALID score and improvement in behavioral symptoms, and a negative association was found with adverse medication effects. Conclusions: The QUALID was sensitive to both the treatment effects and the adverse effects of medication in this sample of patients.

Original languageEnglish (US)
Pages (from-to)82-85
Number of pages4
JournalDementia and Geriatric Cognitive Disorders
Issue number2-3
StatePublished - 2005


  • Dementia
  • Psychotropic drugs
  • Quality of life

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Cognitive Neuroscience
  • Psychiatry and Mental health


Dive into the research topics of 'Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia'. Together they form a unique fingerprint.

Cite this